Color-Changing Sensor Detects Signs of Eye Damage in Tears

(c) UIUC

A new point-of-care rapid-sensing device can detect a key marker of eye injury in minutes – a time frame crucial to treating eye trauma.

Researchers develop sugar-powered sensor to detect and prevent disease

(c) WSU

Researchers at Washington State University have developed an implantable, biofuel-powered sensor that runs on sugar and can monitor a body’s biological signals to detect, prevent and diagnose diseases.

FDA approves HumanOptics AG's CustomFlex Artificial iris

(c) OphthalmologyWeb

The U.S. Food and Drug Administration today approved the first stand-alone prosthetic iris in the United States, a surgically implanted device to treat adults and children whose iris (the colored part of the eye around the pupil) is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye.

FDA grants authorization to 23andMe for direct-to-consumer genetic test for cancer risk

(c) 23andMe

23andMe, Inc. has received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows the company to provide customers, without a prescription, information on three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer.

Diabetes may be a group of five different diseases

(c) CDC

A new analysis published in The Lancet Diabetes and Endocrinology indicates researchers were able to distinguish 5 new subgroups of patients with adult-onset diabetes, representing a first step toward precision medicine for the roughly 415 million patients with the chronic condition.

Ohr Pharmaceuticals' MAKO study utilizing Squalamine and Lucentis does not meet primary endpoint

(c) AAO

Ohr Pharmaceutical, Inc. has reported topline data from the MAKO study that did not meet its primary efficacy endpoint. The study evaluated efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration. The primary efficacy endpoint was the mean visual acuity gain at nine months, using a mixed-effects model for repeated measures (MMRM) analysis.

Removable Drug Delivery Implant based on a Spider's Web to control Type 1 Diabetes

(c) Cornell Univ

For the more than 1 million Americans who live with type 1 diabetes, daily insulin injections are literally a matter of life and death. And while there is no cure, a Cornell-led research team has developed a device that could revolutionize management of the disease.